We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA has approved Merck’s Keytruda (pembrolizumab) for patients with recurrent or metastatic cutaneous squamous cell carcinoma that is not curable by surgery or radiation. Read More
AstraZeneca released full results from a phase 3 trial of its triple combination inhaled therapy Breztri Aerosphere in moderate to severe chronic obstructive pulmonary disease (COPD) patients, finding that it significantly reduced the rate of flare ups compared to two other combination treatments. Read More
As the race to develop an effective COVID-19 vaccine by year’s end gains momentum, the FDA said it plans to issue a guidance on developing and licensing them. Read More
The EMA’s Committee for Medicinal Products for Human Use (CHMP) yesterday recommended granting Gilead Sciences’ remdesivir a conditional marketing authorization as a COVID-19 treatment. Read More
Demand for the corticosteroid dexamethasone has skyrocketed in the days since the University of Oxford published trial results suggesting the drug could be a game-changer for treating severely ill COVID-19 patients, hospital data shows. Read More
Public Citizen has petitioned the FDA to require a black box warning for sodium-glucose cotransporter-2 (SGLT2) inhibitors used off-label for treatment of type 1 diabetes. Read More
New York-based BrainStorm Cell Therapeutics is launching a phase 2 trial of an investigational stem cell treatment for Alzheimer’s disease, using cells derived from patients’ bone marrow. Read More